Our Technology
Innovative Technology. Oncology Focus.
Our Technology
CorriXR Therapeutics has developed an innovative CRISPR/Cas molecule that disables genes in tumor cells responsible for drug resistance. This approach will allow for a broad-based combinatorial therapeutic regimen for the treatment of solid tumors.
Our initial genetic pathway target is the NRF2 gene. The NRF2 protein is a master transcriptional regulator that functions to activate genes in response to cellular stress and is implicated in developing a pro-carcinogenic microenvironment around tumor cells. Our objective is to use CRISPR-directed gene editing to disable NRF2 gene functions in cancer cells. Our preclinical data in both cell and animal models confirms that the NRF2 gene is a viable target for a gene editing therapeutic for solid tumors.
The CorriXR delivery system is a proven lipid nanoparticle approach that when combined with direct intratumoral injection minimizes off-target effects.
Novel Oncology Target for Gene Editing:
NRF2 Pathway
The NRF2 protein is a global transcriptional regulator that functions to activate genes in response to cellular stress. NRF2 maintains homeostasis in terms of normal cell behavior but can also act as an oncogene and help tumor development.
Upregulation of NRF2 by deleterious mutations is found in several tumor types, especially in squamous cell lung cancer. Mutational activation of the KEAP1/NRF2 pathway is connected to therapy resistance.
In human-derived squamous NSCLC in vitro and in vivo animal studies, our data show that disabling NRF2 by gene editing leads to cell death and tumor shrinkage in combination with chemotherapy drugs.
Contact Us
Reach out to discuss partnerships to advance our technology.